aibio
Debt Financing ·
X4 Pharmaceuticals replaces loan with up to $150 million K2 facility
The first $80 million tranche repaid the prior loan in full, including $75 million of principal.
XFOR X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals (XFOR) news XFOR going concern and offering news
Latest X4 Pharmaceuticals news
- Debt Financing
X4 Pharmaceuticals signs up to $150 million senior loan with K2 HealthVentures
The first $80 million tranche repaid $75 million of principal and fees owed under the prior loan. Another $70 million may be available at X4's request, subject to K2HV approval.
- Distress
X4 Pharmaceuticals cuts workforce by 50% in restructuring as four senior executives depart
X4 is cutting about 50% of its workforce for annualized savings of about $13 million, with cash charges of about $3.3 million, after three executives were terminated and its chief medical officer resigned. Its 2024 annual report carried a going-concern warning tied to a loan covenant with Hercules.
- Financings
X4 Pharmaceuticals agrees to $60 million private placement and replaces CEO and CFO
Stifel is sole placement agent for the PIPE, which Coastlands Capital led at $1.42 per share. Closing was expected on or about August 13, 2025.
- Distress
X4 Pharmaceuticals announces restructuring and workforce reduction of 43 employees, about 30%
X4 will close its Vienna facility and pause preclinical programs to focus on mavorixafor in chronic neutropenia. It expects annual spending to fall by $30-35 million and believes its funds will last into the first half of 2026.
X4 Pharmaceuticals annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $6.5 million | $2.6 million |
| Research and development | $72.7 million | $81.6 million |
| Net income (loss) | -$79.2 million | -$37.5 million |
| Cash from operations | -$85.6 million | -$130.9 million |
| Cash and equivalents | $217.0 million | $55.7 million |
Questions about X4 Pharmaceuticals
Has X4 Pharmaceuticals issued a going-concern warning?
Our latest story on this, dated Sep 17, 2025: "X4 Pharmaceuticals cuts workforce by 50% in restructuring as four senior executives depart". The story links the filing or release it is based on. Read the story.
Has X4 Pharmaceuticals raised money recently?
Our latest story on this, dated Aug 12, 2025: "X4 Pharmaceuticals agrees to $60 million private placement and replaces CEO and CFO". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of X4 Pharmaceuticals?
X4 Pharmaceuticals, Inc. trades under the ticker XFOR on NASDAQ.
Where is X4 Pharmaceuticals listed?
X4 Pharmaceuticals, Inc. is listed on NASDAQ.
What is the SEC CIK of X4 Pharmaceuticals?
The SEC Central Index Key (CIK) for X4 Pharmaceuticals, Inc. is 1501697. Its filings are on SEC EDGAR.
How many shares does X4 Pharmaceuticals have outstanding?
99,146,743 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06.
Which country or territory is X4 Pharmaceuticals listed under?
Our directory records X4 Pharmaceuticals, Inc. under United States.
What does X4 Pharmaceuticals do?
Our directory classifies X4 Pharmaceuticals, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of X4 Pharmaceuticals?
The ISIN recorded for X4 Pharmaceuticals, Inc. is US98420X2027.
Does aibio.space cover X4 Pharmaceuticals?
aibio.space lists X4 Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is X4 Pharmaceuticals incorporated?
SEC records list its state or country of incorporation as DE.
What was X4 Pharmaceuticals's revenue last year?
$6.5 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is X4 Pharmaceuticals profitable?
X4 Pharmaceuticals, Inc. reported a net loss of $79.2 million for the fiscal year ended Dec 31, 2025, and used $85.6 million of cash in operations, per its annual report to the SEC.
How much does X4 Pharmaceuticals spend on research and development?
$72.7 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does X4 Pharmaceuticals have?
$195.1 million in cash at Jun 30, 2026, per its 10-Q.
Investor discussion: X4 Pharmaceuticals
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Financings
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,1.02,2.03,3.02,7.01,9.01). Source
- Financings
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
- Financings
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
- Distress
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,5.02,7.01,9.01). Source
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,8.01,9.01). Source
- Financings
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
- Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 2.02,7.01). Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 5.03,8.01,9.01). Source
- Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
- Distress
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,7.01,9.01). Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Stock chart
SEC filings and registration
- SEC name
- X4 Pharmaceuticals, Inc
- CIK
- 1501697
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- US tickers
- XFOR (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 61 NORTH BEACON STREET, BOSTON, MA, 02134
- Phone
- 857-529-8300
- Shares outstanding
- 99,146,743 as of 2026-07-31 (10-Q filed 2026-08-06)
- Former names
- Arsanis, Inc.
Recent filings
Listing details
- Company
- X4 Pharmaceuticals, Inc.
- Ticker
- XFOR
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Biotechnology
- ISIN
- US98420X2027
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction